Amicus Therapeutics Stock Analysis

Amicus Stock Analysis Notes

About 99.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 0.51. Amicus Therapeutics last dividend was issued on the 31st of August 2009. Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania. Amicus Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 496 people. To learn more about Amicus Therapeutics call Bradley MBA at 609 662 2000 or check out https://amicusrx.com.

Amicus Therapeutics Investment Alerts

Amicus Therapeutics Upcoming and Recent Events

Amicus Largest EPS Surprises

View All Earnings Estimates

Amicus Stock Institutional Investors

Note, although Amicus Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Amicus Market Capitalization

The company currently falls under 'Mid-Cap' category with a current market capitalization of 3.05 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Amicus Therapeutics's market, we take the total number of its shares issued and multiply it by Amicus Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.

Amicus Profitablity

The company has Profit Margin (PM) of (0.38) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.03) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.03.

Management Efficiency

Amicus Therapeutics has return on total asset (ROA) of (0.0612) % which means that it has lost $0.0612 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.0704) %, meaning that it created substantial loss on money invested by shareholders. Amicus Therapeutics' management efficiency ratios could be used to measure how well Amicus Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of April 19, 2024, Return On Tangible Assets is expected to decline to -0.28. In addition to that, Return On Capital Employed is expected to decline to -0.13. At present, Amicus Therapeutics' Non Currrent Assets Other are projected to increase significantly based on the last few years of reporting. The current year's Intangibles To Total Assets is expected to grow to 0.39, whereas Other Assets are forecasted to decline to about 41.8 M.

Technical Drivers

As of the 19th of April, Amicus Therapeutics shows the Risk Adjusted Performance of (0.06), standard deviation of 2.52, and Mean Deviation of 1.91. Amicus Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to break down and interpolate thirteen technical drivers for Amicus Therapeutics, which can be compared to its peers. Please confirm Amicus Therapeutics information ratio, as well as the relationship between the value at risk and kurtosis to decide if Amicus Therapeutics is priced correctly, providing market reflects its regular price of 10.33 per share. Given that Amicus Therapeutics has information ratio of (0.14), we suggest you to validate Amicus Therapeutics's prevailing market performance to make sure the company can sustain itself at a future point.

Amicus Therapeutics Price Movement Analysis

Amicus Therapeutics Insider Trading Activities

Amicus Therapeutics Predictive Daily Indicators

Amicus Therapeutics Corporate Filings

Amicus Therapeutics Forecast Models

Amicus Therapeutics' time-series forecasting models are one of many Amicus Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Amicus Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Amicus Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Amicus shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Amicus Therapeutics. By using and applying Amicus Stock analysis, traders can create a robust methodology for identifying Amicus entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Amicus analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Amicus analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Amicus Therapeutics stock analysis indicators help investors evaluate how Amicus Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Amicus Therapeutics shares will generate the highest return on investment. By understating and applying Amicus Therapeutics stock analysis, traders can identify Amicus Therapeutics position entry and exit signals to maximize returns.

Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Amicus Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. For information on how to trade Amicus Stock refer to our How to Trade Amicus Stock guide.You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.

When running Amicus Therapeutics' price analysis, check to measure Amicus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Amicus Therapeutics is operating at the current time. Most of Amicus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Amicus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Amicus Therapeutics' price. Additionally, you may evaluate how the addition of Amicus Therapeutics to your portfolios can decrease your overall portfolio volatility.

Is Amicus Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Amicus Therapeutics. If investors know Amicus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Amicus Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

The market value of Amicus Therapeutics is measured differently than its book value, which is the value of Amicus that is recorded on the company's balance sheet. Investors also form their own opinion of Amicus Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Amicus Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Amicus Therapeutics' market value can be influenced by many factors that don't directly affect Amicus Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Amicus Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Amicus Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Amicus Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.